The United Kingdom is placing a massive bet on the future of neuroscience. Through its newly formed Advanced Research and Innovation Agency (ARIA), the UK government is moving away from incremental science and toward “moonshot” projects—high-risk, high-reward research designed to solve some of humanity’s most intractable problems.
One of the most ambitious pillars of this strategy is a £69 million initiative dedicated to modulating the human brain at the level of its internal circuitry.
The Problem: A Lack of Precision
Current medical interventions for neurological disorders often act like a “broad brush,” affecting large areas of the brain without targeting the specific source of the problem. This lack of precision is a major hurdle in treating conditions such as epilepsy, Alzheimer’s, depression, and addiction.
According to ARIA program director Jacques Carolan, these diverse conditions share a common thread: they are all disorders of brain circuitry.
– Some circuits are overconnected.
– Some are underconnected.
– Certain brain regions or cell types may be malfunctioning.
The goal of the ARIA program is to move beyond general treatments and develop neurotechnologies that interface at the circuit level, allowing doctors to interact with the brain with surgical precision.
The Innovation: From Ultrasound to Gene Therapy
To tackle this challenge, ARIA has already funded 19 different research teams exploring diverse technological frontiers. Key areas of focus include:
- Advanced Ultrasound: Researchers are looking at ultrasound not just as a way to modulate brain activity, but as a tool to “biotype” a patient’s brain, providing a unique map of their specific neural connections.
- Real-time Imaging: A team at Imperial College London is combining ultrasound with gene therapy to visualize gene expression within neurons in real-time. This could allow scientists to see exactly why certain networks are failing.
- Next-Generation Stimulation: Building on the success of deep brain stimulation used for Parkinson’s disease, researchers aim to create “platform technologies.” The hope is to develop methods that can treat various conditions—including addiction and depression—without necessarily requiring invasive surgery.
The “Moderna Effect”: Why High-Risk Funding Matters
Investing heavily in unproven technology is inherently risky. However, ARIA’s leadership argues that these “moonshots” are essential for long-term societal breakthroughs.
ARIA CEO Kathleen Fisher, a former official at the US agency DARPA (the model for ARIA), pointed to a historical precedent to justify this approach. In 2013, DARPA funded research into rapid vaccine platforms. That investment helped birth Moderna, a company whose mRNA technology became a cornerstone in the global response to the COVID-19 pandemic.
While the full impact of ARIA’s brain research may not be realized immediately, the agency is looking for “seedlings of impact” by the early 2030s. Even if the research doesn’t produce a complete cure within seven years, the goal is to provide enough clinical evidence to prove that non-surgical, circuit-level brain intervention is possible.
“It might be that we’re starting to see trials that show we can do circuit-level interventions in a way that doesn’t require surgery,” says Fisher.
Conclusion
By targeting the fundamental circuitry of the brain, the UK aims to transform neurological care from managing symptoms to precision-tuning the mind. Whether through ultrasound or gene-integrated imaging, the success of this program could redefine how we treat the most complex disorders of the human experience.
